2026 Global: Antibody Discovery Market-Competitive Review (2032) report
Description
The 2026 Global: Antibody Discovery Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for antibody discovery market by geography and historical trend. The scope of the report extends to sizing of the antibody discovery market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
AbCellera, Genmab, Regeneron, WuXi Biologics, Adimab, Lonza, AstraZeneca (MedImmune), Amgen, Pfizer, and Roche/Genentech are widely cited among the major companies shaping the antibody discovery market due to their combined strengths in proprietary discovery platforms, extensive pipelines, and strategic partnerships. AbCellera leverages single‑cell screening and AI partnerships to accelerate lead identification and has become a preferred collaborator for both biotech and large pharma. Genmab is recognized for its bispecific and next‑generation antibody programs and strong in‑house discovery capabilities that feed a broad oncology and immunology pipeline. Regeneron’s VelociSuite technologies and integrated discovery-to-development model underpin a consistent stream of antibody candidates and approved therapeutics across multiple indications. WuXi Biologics’ end‑to‑end services and global CRO footprint make it a leading external partner for antibody discovery and early development for clients worldwide.
Adimab and Lonza occupy complementary roles as platform innovator and development/manufacturing partner respectively, with Adimab’s yeast display and rapid screening platforms driving discovery for partners and Lonza offering scale‑up and CMC services that bridge discovery to commercialization. AstraZeneca’s MedImmune unit contributes advanced antibody engineering and bispecific expertise within a broad oncology and respiratory biologics portfolio that benefits from deep discovery capabilities and external collaborations. Amgen’s antibody discovery strength is supported by long‑standing biologics R&D, proprietary platforms, and a commercial portfolio of monoclonal antibodies across oncology and inflammatory diseases that sustains its leadership position. Pfizer’s large biologics pipeline, investments in ADCs and bispecifics, and extensive discovery collaborations keep it prominent in antibody discovery and downstream development.
Roche/Genentech, as a historic leader in monoclonal antibody therapeutics, combines decades of discovery experience, personalized medicine strategies, and a dense oncology immunotherapy pipeline that continues to shape market standards. Collectively these ten companies drive the market through a mix of in‑house platform innovation, strategic outsourcing, and transactional licensing—factors frequently highlighted in market reports and industry analyses as primary drivers of market growth and consolidation. Reports and market forecasts additionally note that specialized service providers and platform companies (e.g., Twist Bioscience, Charles River, Thermo Fisher, Evotec) interact with these major players to supply enabling technologies, reinforcing an ecosystem where large pharma both competes and collaborates to accelerate antibody discovery and commercialization.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for antibody discovery market by geography and historical trend. The scope of the report extends to sizing of the antibody discovery market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
AbCellera, Genmab, Regeneron, WuXi Biologics, Adimab, Lonza, AstraZeneca (MedImmune), Amgen, Pfizer, and Roche/Genentech are widely cited among the major companies shaping the antibody discovery market due to their combined strengths in proprietary discovery platforms, extensive pipelines, and strategic partnerships. AbCellera leverages single‑cell screening and AI partnerships to accelerate lead identification and has become a preferred collaborator for both biotech and large pharma. Genmab is recognized for its bispecific and next‑generation antibody programs and strong in‑house discovery capabilities that feed a broad oncology and immunology pipeline. Regeneron’s VelociSuite technologies and integrated discovery-to-development model underpin a consistent stream of antibody candidates and approved therapeutics across multiple indications. WuXi Biologics’ end‑to‑end services and global CRO footprint make it a leading external partner for antibody discovery and early development for clients worldwide.
Adimab and Lonza occupy complementary roles as platform innovator and development/manufacturing partner respectively, with Adimab’s yeast display and rapid screening platforms driving discovery for partners and Lonza offering scale‑up and CMC services that bridge discovery to commercialization. AstraZeneca’s MedImmune unit contributes advanced antibody engineering and bispecific expertise within a broad oncology and respiratory biologics portfolio that benefits from deep discovery capabilities and external collaborations. Amgen’s antibody discovery strength is supported by long‑standing biologics R&D, proprietary platforms, and a commercial portfolio of monoclonal antibodies across oncology and inflammatory diseases that sustains its leadership position. Pfizer’s large biologics pipeline, investments in ADCs and bispecifics, and extensive discovery collaborations keep it prominent in antibody discovery and downstream development.
Roche/Genentech, as a historic leader in monoclonal antibody therapeutics, combines decades of discovery experience, personalized medicine strategies, and a dense oncology immunotherapy pipeline that continues to shape market standards. Collectively these ten companies drive the market through a mix of in‑house platform innovation, strategic outsourcing, and transactional licensing—factors frequently highlighted in market reports and industry analyses as primary drivers of market growth and consolidation. Reports and market forecasts additionally note that specialized service providers and platform companies (e.g., Twist Bioscience, Charles River, Thermo Fisher, Evotec) interact with these major players to supply enabling technologies, reinforcing an ecosystem where large pharma both competes and collaborates to accelerate antibody discovery and commercialization.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.